The article focuses on patient-reported outcomes (PROs) in relation to implantable cardioverter-defibrillators (ICDs) from the ATLAS trial comparing subcutaneous and transvenous devices. Topics include the role of ICDs in patient quality of life and psychological impact, the use of specific and generic instruments to measure PROs, and the findings from the ATLAS trial regarding device acceptance and health-related quality of life scores.